as 02-04-2025 2:34pm EST
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
Founded: | 2006 | Country: | United States |
Employees: | N/A | City: | SUNNYVALE |
Market Cap: | 98.7M | IPO Year: | N/A |
Target Price: | $9.40 | AVG Volume (30 days): | 184.9K |
Analyst Decision: | Hold | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -15.16 | EPS Growth: | N/A |
52 Week Low/High: | $2.65 - $16.52 | Next Earning Date: | 01-28-2025 |
Revenue: | $208,775,000 | Revenue Growth: | -15.81% |
Revenue Growth (this year): | 21.93% | Revenue Growth (next year): | 17.31% |
ME Breaking Stock News: Dive into ME Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Quartz
5 days ago
MedTech Dive
6 days ago
Medical Device Network
7 days ago
GuruFocus.com
7 days ago
Quartz
7 days ago
MT Newswires
7 days ago
GlobeNewswire
8 days ago
The information presented on this page, "ME 23andMe Holding Co. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.